TG Therapeutics is a commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, Co. has received approval from the U.S. Food and Drug Administration for BRIUMVI™ (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Co. also evaluates products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. We show 50 historical shares outstanding datapoints in our TGTX shares outstanding history coverage, used to compute TGTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TGTX market cap history over the course of time is important for investors
interested in comparing TGTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TGTX versus a peer is one thing; comparing
TGTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TGTX can fluctuate over the course of history.
With this page we aim to empower investors researching TGTX by allowing them to research the TGTX market cap history. |
Free TGTX Email Alerts:
Video: The Importance of Market Cap
